Spots Global Cancer Trial Database for idarubicin
Every month we try and update this database with for idarubicin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia | NCT00487448 | Myelodysplastic... Acute Myeloblas... | Fludarabine Cytarabine G-CSF Idarubicin Peripheral bloo... Bone marrow tra... | - 75 Years | PETHEMA Foundation | |
| Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia | NCT00002549 | Leukemia | filgrastim busulfan cyclophosphamid... cytarabine daunorubicin hy... etoposide idarubicin mesna mitoxantrone hy... allogeneic bone... autologous bone... peripheral bloo... radiation thera... | 15 Years - 60 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma | NCT00003639 | Lymphoma | recombinant int... chlorambucil dexamethasone idarubicin | 15 Years - 70 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia | NCT00003602 | Leukemia Myelodysplastic... | cytarabine etoposide idarubicin mitoxantrone hy... | 55 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Acute Leukemia | NCT00004905 | Leukemia | filgrastim recombinant int... cyclophosphamid... cytarabine etoposide idarubicin peripheral bloo... radiation thera... | 18 Years - 60 Years | National Cancer Institute (NCI) | |
| Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia | NCT03860844 | Acute Lymphobla... Acute Myeloid L... | Isatuximab Dexamethasone o... Fludarabine Cytarabine Liposomal dauno... Daunorubicin (n... Idarubicin Filgrastim or e... Mitoxantrone Doxorubicin Vincristine Pegaspargase (P... Cyclophosphamid... Etoposide Methotrexate L - Asparginase Hydroxyurea L - Asparaginas... | 28 Days - 17 Years | Sanofi | |
| Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006) | NCT00542971 | AML Acute Myeloid L... Myelodysplastic... | Idarubicin Sorafenib Ara-C | 15 Years - 60 Years | M.D. Anderson Cancer Center | |
| Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine | NCT01180322 | Acute Myeloid L... | Cytarabine Idarubicin Etoposide Azacitidine Lenograstim | 18 Years - | University of Ulm | |
| Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years | NCT00464217 | Acute Myeloblas... | ARA-C Idarubicin Leucomax | 65 Years - | PETHEMA Foundation | |
| TACE Using Idarubicin Versus Doxorubicin Chemoemulsion in Patients With Hepatocellular Carcinoma (IDADOX) | NCT06114082 | Hepatocellular ... Liver Cancer | IDA-TACE DOX-TACE | 19 Years - | Seoul National University Hospital | |
| Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine | NCT01180322 | Acute Myeloid L... | Cytarabine Idarubicin Etoposide Azacitidine Lenograstim | 18 Years - | University of Ulm | |
| Chemoembolisation of Non Resectable, Non Metastatic Hepatocellular Carcinomas | NCT01040559 | Carcinoma, Hepa... | idarubicin | 18 Years - | Centre Hospitalier Universitaire Dijon | |
| A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia. | NCT02310321 | Acute Myeloid L... FLT3-mutated Ac... | gilteritinib Idarubicin Cytarabine | 18 Years - 69 Years | Astellas Pharma Inc | |
| Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia | NCT00093483 | Leukemia | filgrastim arsenic trioxid... cytarabine idarubicin | 18 Years - 59 Years | Roswell Park Cancer Institute | |
| Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia | NCT00002761 | Leukemia | filgrastim recombinant int... busulfan cyclophosphamid... cyclosporine cytarabine idarubicin peripheral bloo... | 18 Years - 60 Years | Columbia University | |
| Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment | NCT02881086 | Acute Lymphobla... Lymphoblastic L... | Rituximab Nelarabine PEG-Asparaginas... Cranial irradia... Imatinib Idarubicin Dexamethasone Cyclophosphamid... Fludarabine Vincristine Mercaptopurine VP16 Daunorubicin (D... Methotrexate Stem cell trans... Cytarabine Vindesine Adriamycin Prednisolone | 18 Years - 55 Years | Goethe University | |
| Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL | NCT03564704 | Leukemia Leukemia, Acute Adult Lymphobla... Leukemia, Lymph... Leukemia, T Cel... Adult Acute Lym... Lymphoblastic L... Lymphoblastic L... | Dexamethasone vincristine Cyclophosphamid... Idarubicin Pegaspargase Adriamycin Methotrexate 6-mercaptopurin... Etoposide Cytarabine Bone marrow asp... Intrathecal inj... Radiation thera... NGS allogeneic hema... Flow-MRD FISH Flow immunophen... Karyotyping Chidamide PET-CT scan | 14 Years - 55 Years | Nanfang Hospital, Southern Medical University | |
| Venetoclax + Azacitidine vs. Induction Chemotherapy in AML | NCT04801797 | Acute Myeloid L... | Cytarabine Idarubicin Daunorubicin Liposomal dauno... Venetoclax Azacitidine | 18 Years - | Massachusetts General Hospital | |
| Combination Chemotherapy in Treating Patients With Lymphoma | NCT00002835 | Lymphoma | Bleomycin Sulfa... Filgrastim (G-C... Recombinant Int... Carmustine Cisplatin (CDDP... Cyclophosphamid... Cytarabine (ARA... Etoposide (VP-1... Idarubicin Ifosfamide Leucovorin Calc... Melphalan Methotrexate Methylprednisol... mitoxantrone hy... Vincristine Sul... Peripheral Bloo... Radiation Thera... | 15 Years - 59 Years | M.D. Anderson Cancer Center | |
| Amifostine and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | NCT00003268 | Drug/Agent Toxi... Leukemia | amifostine trih... cytarabine idarubicin | 18 Years - | National Cancer Institute (NCI) | |
| Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation | NCT02632708 | Newly Diagnosed... Untreated AML AML Arising Fro... AML Arising Fro... AML Arising Aft... | AG-120 AG-221 cytarabine daunorubicin idarubicin mitoxantrone etoposide | 18 Years - | Servier | |
| Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML) | NCT02441803 | Leukemia | Busulfan Fludarabine Clofarabine Total Body Irra... Thymoglobulin Stem Cell Infus... Cyclophosphamid... Tacrolimus Mycophenolate m... Decitabine Cytarabine Idarubicin | 18 Years - 60 Years | M.D. Anderson Cancer Center | |
| Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia | NCT00528450 | Leukemia | arsenic trioxid... idarubicin tretinoin | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome | NCT00002800 | Leukemia Myelodysplastic... Neutropenia | filgrastim lintuzumab cytarabine etoposide idarubicin | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia | NCT00003758 | Leukemia | cytarabine idarubicin allogeneic bone... autologous bone... peripheral bloo... | 15 Years - 60 Years | National Cancer Institute (NCI) | |
| A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia | NCT01773408 | Myelogenous Leu... | RO5503781 MBP RO5503781 SDP Idarubicin Daunorubicin Cytarabine | 18 Years - | Hoffmann-La Roche | |
| Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia | NCT00528398 | Leukemia | cytarabine idarubicin | 16 Years - 60 Years | City of Hope Medical Center | |
| Bendamustine and Idarubicin in Treating Older Patients With Previously Untreated AML or MDS | NCT01141725 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... de Novo Myelody... Myelodysplastic... Untreated Adult... | bendamustine hy... idarubicin | 50 Years - | Fred Hutchinson Cancer Center | |
| Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia | NCT02873338 | Acute Myeloid L... | Dociparstat sod... Idarubicin Cytarabine | 60 Years - | Chimerix | |
| Efficacy and Toxicity of Increasing Doses of Idarubicin, Cytarabine and G-CSF in Acute Myeloid Leukemia | NCT01700413 | Di Novo Acute M... | Idarubicin | 18 Years - 70 Years | Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias | |
| Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) in Patients With Multiple Myeloma | NCT00124813 | Multiple Myelom... | thalidomide idarubicin | 18 Years - | University Hospital, Bonn | |
| Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia | NCT00006122 | Leukemia | cytarabine etoposide gemtuzumab ozog... idarubicin mitoxantrone hy... | 61 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML | NCT03661515 | Acute Myeloid L... | Selinexor fludarabine idarubicin cytarabine G-CSF | 18 Years - 65 Years | PETHEMA Foundation | |
| Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia | NCT00002532 | Leukemia | filgrastim asparaginase cytarabine daunorubicin hy... dexamethasone etoposide idarubicin ifosfamide leucovorin calc... methotrexate prednisolone vindesine | 15 Years - 65 Years | National Cancer Institute (NCI) | |
| Efficacy of G-CSF-Priming in Elderly AML Patients | NCT00199147 | Acute Myeloid L... | Cytarabine Etoposide Idarubicin G-CSF Fludarabine Stem cell apher... Stem cell trans... | 61 Years - | Johann Wolfgang Goethe University Hospital | |
| Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result | NCT00146120 | Acute Myeloid L... | Idarubicin Cytosin-Arabino... Etoposide All-trans Retin... | 16 Years - 60 Years | University of Ulm | |
| Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia | NCT00016159 | Leukemia | filgrastim lintuzumab arsenic trioxid... idarubicin tretinoin | - | Memorial Sloan Kettering Cancer Center | |
| Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT04047641 | Acute Myeloid L... Blasts 20 Perce... High Risk Myelo... Recurrent Acute... Recurrent Acute... Recurrent High ... Refractory Acut... Refractory High... | Cladribine Cytarabine Idarubicin Quizartinib | 18 Years - | M.D. Anderson Cancer Center | |
| Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML) | NCT04107727 | Acute Myeloid L... | Quizartinib Placebo oral ta... Cytarabine Idarubicin | 18 Years - 70 Years | PETHEMA Foundation | |
| Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R | NCT00534469 | Leukemia | aldesleukin filgrastim busulfan cytarabine etoposide idarubicin autologous hema... bone marrow tra... peripheral bloo... total-body irra... | 16 Years - 60 Years | City of Hope Medical Center | |
| Combination Chemotherapy in Treating Children With Relapsed or Refractory Acute Lymphocytic Leukemia | NCT00003729 | Leukemia | cytarabine fludarabine pho... idarubicin | - 17 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Adoptive Transfer of Haplo-identical DLI for AML and MDS | NCT02046122 | Acute Myeloid L... Myelodysplastic... | Idarubicin Cytarabine DLI | 55 Years - | Duke University | |
| Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML | NCT02560025 | Acute Myeloid L... | Alisertib Cytarabine Idarubicin Daunorubicin | 18 Years - | Massachusetts General Hospital | |
| Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children | NCT05313958 | Leukemia, Monoc... Pediatric AML | Cladribine G-CSF Cytarabine Idarubicin Mitoxantrone Sorafenib | 1 Month - 14 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome | NCT00002989 | Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | busulfan cyclophosphamid... idarubicin melphalan radiation thera... | 16 Years - 60 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma | NCT00002565 | Lymphoma | bleomycin sulfa... CHOP regimen cisplatin cyclophosphamid... cytarabine doxorubicin hyd... etoposide idarubicin ifosfamide mesna methylprednisol... mitoxantrone hy... prednisone vincristine sul... | 15 Years - | M.D. Anderson Cancer Center | |
| Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia | NCT00002549 | Leukemia | filgrastim busulfan cyclophosphamid... cytarabine daunorubicin hy... etoposide idarubicin mesna mitoxantrone hy... allogeneic bone... autologous bone... peripheral bloo... radiation thera... | 15 Years - 60 Years | National Cancer Institute (NCI) | |
| Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT00801489 | Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... de Novo Myelody... High Risk Myelo... Inv(16) Myelodysplastic... t(16;16) t(8;21) Untreated Adult... | Cytarabine Decitabine Filgrastim-sndz Fludarabine Pho... Gemtuzumab Ozog... Idarubicin Laboratory Biom... | 18 Years - | M.D. Anderson Cancer Center | |
| Acute Promyelocytic Leukemia 2006 (APL) | NCT00378365 | Leukemia, Promy... | Arsenic trioxid... ATRA | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AML | NCT05053425 | Acute Myeloid L... | Venetoclax Azacitidine Cladribine Cytarabine Idarubicin | 60 Years - | LanZhou University | |
| AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen | NCT01018069 | Leukemia | AEG35156 | 18 Years - | Aegera Therapeutics | |
| Phase I/II Study of Escalating Doses of Idarubicin Orally Given With Oral Cyclophosphamide, Etoposide, Prednisolone and Intravenous Rituximab in Elderly Patient With Disseminated High Grade Non Hodgkin Lymphoma | NCT01958996 | High Grade Lymp... | idarubicin | 65 Years - 80 Years | Poitiers University Hospital | |
| Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment | NCT02881086 | Acute Lymphobla... Lymphoblastic L... | Rituximab Nelarabine PEG-Asparaginas... Cranial irradia... Imatinib Idarubicin Dexamethasone Cyclophosphamid... Fludarabine Vincristine Mercaptopurine VP16 Daunorubicin (D... Methotrexate Stem cell trans... Cytarabine Vindesine Adriamycin Prednisolone | 18 Years - 55 Years | Goethe University | |
| Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL) | NCT00199186 | Philadelphia Po... Lymphoid Blasti... | imatinib vincristine cyclophosphamid... cytosine arabin... dexamethasone idarubicin methotrexate (i... AraC (intrathec... dexamethasone (... | 56 Years - | Johann Wolfgang Goethe University Hospital | |
| Chemotherapy, Interferon, and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia | NCT00002771 | Leukemia | recombinant int... busulfan cytarabine hydroxyurea idarubicin allogeneic bone... autologous bone... peripheral bloo... radiation thera... | - | National Cancer Institute (NCI) | |
| Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia | NCT00002926 | Leukemia Myelodysplastic... | cytarabine etoposide idarubicin allogeneic bone... peripheral bloo... | 16 Years - 60 Years | National Cancer Institute (NCI) | |
| Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia | NCT00052299 | Leukemia | cytarabine etoposide gemtuzumab ozog... idarubicin mitoxantrone hy... | 61 Years - 75 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine | NCT01180322 | Acute Myeloid L... | Cytarabine Idarubicin Etoposide Azacitidine Lenograstim | 18 Years - | University of Ulm | |
| Risk-adapted Therapy for Primary Acute Myeloid Leukemia | NCT04687098 | Leukemia, Myelo... | Idarubicin Ara-C G-CSF Allogeneic matc... Autologous peri... Measurable resi... | 17 Years - 70 Years | Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias | |
| Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | NCT02834390 | Acute Myeloid L... | Quizartinib Cytarabine Idarubicin Daunorubicin | 20 Years - 75 Years | Daiichi Sankyo | |
| Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia | NCT02144675 | Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Recurrent Adult... Untreated Adult... | choline magnesi... idarubicin cytarabine laboratory biom... | 18 Years - | Rutgers, The State University of New Jersey | |
| Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia | NCT00967057 | Leukemia | asparaginase dexamethasone idarubicin methotrexate mitoxantrone hy... pegaspargase vincristine sul... | 1 Year - 18 Years | National Cancer Institute (NCI) | |
| Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia | NCT00528398 | Leukemia | cytarabine idarubicin | 16 Years - 60 Years | City of Hope Medical Center | |
| Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia | NCT06001788 | AML AML With Mutate... Hematologic Mal... KMT2Ar NPM1 Mutation MLL Rearrangeme... Leukemia Acute Myeloid L... Leukemia, Myelo... Leukemia, Myelo... Acute Leukemia Neoplasms by Hi... | Ziftomenib Fludarabine Idarubicin Cytarabine Gilteritinib Granulocyte col... | 18 Years - | Kura Oncology, Inc. | |
| Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML | NCT02560025 | Acute Myeloid L... | Alisertib Cytarabine Idarubicin Daunorubicin | 18 Years - | Massachusetts General Hospital | |
| Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia | NCT01876953 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Recurrent Adult... Secondary Acute... Untreated Adult... | cytarabine idarubicin dasatinib laboratory biom... | 18 Years - | City of Hope Medical Center | |
| Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma | NCT03117751 | Acute Lymphobla... Acute Lymphobla... | Prednisone Vincristine Daunorubicin Pegaspargase Erwinase® Cyclophosphamid... Cytarabine Mercaptopurine Dasatinib Methotrexate Blinatumomab Ruxolitinib Bortezomib Dexamethasone Doxorubicin Etoposide Clofarabine Vorinostat Idarubicin Nelarabine Thioguanine Asparaginase Er... Calaspargase Pe... | 1 Year - 18 Years | St. Jude Children's Research Hospital | |
| Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia | NCT02144675 | Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Recurrent Adult... Untreated Adult... | choline magnesi... idarubicin cytarabine laboratory biom... | 18 Years - | Rutgers, The State University of New Jersey | |
| Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT02635074 | Recurrent Adult... | Cytarabine Ibrutinib Idarubicin | 18 Years - | Stanford University | |
| Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia | NCT03214562 | High Risk Myelo... Recurrent Acute... Refractory Acut... | Cytarabine Filgrastim Fludarabine Idarubicin Pegfilgrastim Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS | NCT06050941 | Acute Myeloid L... Myelodysplastic... | idarubicin Cytarabine | 18 Years - 60 Years | First Affiliated Hospital of Zhejiang University | |
| Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma | NCT00003639 | Lymphoma | recombinant int... chlorambucil dexamethasone idarubicin | 15 Years - 70 Years | National Cancer Institute (NCI) | |
| Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers | NCT03589729 | Acute Myeloid L... Blast Phase Chr... Blasts 10 Perce... High Risk Myelo... Myeloid Sarcoma Myeloproliferat... Philadelphia Ch... | Cladribine Cytarabine Dexrazoxane Hyd... Gemtuzumab Ozog... Idarubicin | 12 Years - | M.D. Anderson Cancer Center | |
| Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia | NCT00003405 | Leukemia | recombinant int... amifostine trih... bromodeoxyuridi... cytarabine idarubicin idoxuridine isotretinoin mitoxantrone hy... | 0 Years - 70 Years | Rush University Medical Center | |
| A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia | NCT01035502 | Acute Myeloid L... | Elacytarabine p... | 18 Years - | Clavis Pharma | |
| Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia | NCT00002658 | Leukemia Neutropenia | filgrastim amsacrine cyclophosphamid... cytarabine daunorubicin hy... etoposide idarubicin mitoxantrone hy... thioguanine tretinoin allogeneic bone... autologous bone... peripheral bloo... radiation thera... | 15 Years - | National Cancer Institute (NCI) | |
| Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia | NCT00838240 | Leukemia Myelodysplastic... | clofarabine cytarabine idarubicin | 18 Years - 60 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015) | NCT03390387 | Childhood Acute... | Dexamethasone c... Dexamethasone i... Dexamethasone Methylprednisol... Daunorubicin Idarubicin Bortezomib Second phase of... Standard induct... Standard consol... | 1 Year - 50 Years | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | |
| Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome | NCT00002798 | Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Myelo... Chronic Myelomo... de Novo Myelody... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Anem... Secondary Myelo... Untreated Child... | asparaginase daunorubicin hy... fludarabine pho... therapeutic hyd... allogeneic bone... 3-dimensional c... filgrastim cytarabine idarubicin dexamethasone thioguanine etoposide methotrexate cyclophosphamid... aldesleukin busulfan | - 21 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia | NCT00002812 | Leukemia | asparaginase cyclophosphamid... cytarabine daunorubicin hy... dexamethasone doxorubicin hyd... idarubicin mercaptopurine methotrexate pegaspargase prednisone thioguanine vincristine sul... radiation thera... | 1 Year - 21 Years | Children's Oncology Group |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
